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ABSTRACT
Background. The purpose of this retrospective, popula-
tion-based, cohort study was to identify patient and tumor
characteristics that are associated with a high risk of tumor-
positive margins after breast-conserving surgery (BCS) to
optimize preoperative counseling.
Methods. All patients with invasive breast cancer (IBC)
reported according to the synoptic reporting module in the
Dutch Pathology Registry between 2009 and 2015 were
included (n = 42.048 cases). Data extraction included age,
type of surgery, several tumor characteristics, and resection
margin status according to the Dutch indications for re-
excision (free, focally positive, or more than focally posi-
tive). Univariate and multivariate tests were used to
determine the association between clinicopathological
features and margin status, restricted to patients with BCS.
Results. Of 42,048 cases, a total of 25,315 cases (60.2 %)
with IBC underwent BCS. Of these patients, 2578 patients
(10.2 %) had focally positive resection margins and 1665
(6.6 %) had more than focally positive resection margins.
By univariate analysis, the following features were
significantly associated with involved margins:
age\ 60 years, multifocality, lobular subtype, tumor size
[2 cm, intermediate- and high-grade, positive ER status,
positive Her2 status, angio-invasion, and the presence/ex-
tent of a ductal carcinoma in situ (DCIS) component. In
multivariate logistic regression, the variables with the
strongest association with involved margins (OR[ 2) were
multifocality, lobular subtype, large tumor size, and the
presence of DCIS.
Conclusions. Several clinicopathologic features are asso-
ciated with involved resection margins after BCS for IBC.
Assessment of these features preoperatively could be used
to optimize preoperative counseling.
Patients with early invasive breast cancer (IBC) who
undergo breast-conserving surgery (BCS) followed by
radiotherapy have a survival that is similar to patients who
undergo a mastectomy.1,2 BCS provides better cosmesis
compared with a mastectomy, but patients with BCS have a
higher risk of involved resection margins, which is asso-
ciated with an increased local recurrence risk.3,4 However,
there is no international consensus regarding the definition
of an optimal resection margin after BCS, resulting in
substantial variation in surgical practice worldwide.5,6
Clearly, secondary re-excisions to attain wider margins
result in increased costs, complications, discomfort, and
have a negative effect on cosmesis.
Recently, the Society of Surgical Oncology (SSO) and the
American Society for Radiation Oncology (ASTRO) pub-
lished a multidisciplinary consensus guideline regarding
surgical margins for patients with Stage I and II IBC
undergoing BCS and whole-breast irradiation.7 According to
this guideline, no ink on the tumor is regarded as the standard
for an adequate margin. This is in line with the results of a
meta-analysis that confirmed that local recurrences are
reduced by negative resection margins.6 Increasing the dis-
tance required for the definition of a negative resection
margin was weakly associated with a reduced local recur-
rence rate, although this effect was not significant after
adjustment for covariates. In the Netherlands, however, the
indications for a re-excision are even less stringent.
According to the Dutch treatment guideline for breast can-
cer, margin status is defined as free (no ink on tumor), focally
positive, or more than focally positive.8 Re-excision is
indicated only for those patients with a more than focally
positive resection margin. In contrast, patients with a focally
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positive resection margin do not undergo re-excision
according to this guideline, because a radiation-boost is held
to result in adequate local control and overall survival.9–11
Additional studies or consensus meetings could lead to a
more uniform definition of optimal resection margin status
and indication for re-excision, but regardless of the exact
definitions, tumor-positive resection margins are regarded as a
strong predictor for local recurrence. Therefore, preoperative
prediction of the likelihood of positive resection margins
could result in improved counseling regarding surgery and
potentially a reduction in the number of re-excisions. Several
studies reported on predictive factors for surgical margin
status in BCS.12–16 However, the majority of these studies are
relatively small, single-center studies, hampering the utility of
the findings in daily practice. In the Netherlands, synoptic
reporting of breast cancer is used, which offers a unique
opportunity for a large, nationwide, retrospective cohort
study. In this study, we report several clinical and pathologic
factors that are associated with focal or more than focally
positive resection margins after BCS, providing important
information that can be used to optimize preoperative
counseling.
PATIENTS AND METHODS
Data Acquisition
In the Netherlands, all pathology reports are archived in
the Dutch Pathology Registry (PALGA).17 Since 2009,
synoptic reporting modules for reporting several common
tumor types have been available, including breast cancer.
In these modules, the parameters are captured in numerous
variables instead of free text fields, which offers the
opportunity to analyze all reports simultaneously.
Patient and Tumor Characteristics
All consecutive patients with IBC reported according to
the protocol-module in the Netherlands between January 1,
2009 and September 1, 2015 were included (n = 42,048
cases). We excluded patients with pure DCIS or patients with
IBC after previous treatment (re-excisions after a previous
irradical resection, neoadjuvant therapy). Patients with
bilateral IBC were included as two cases. Where there was
multifocality of tumor in one breast, the largest IBC was
included for analysis of tumor characteristics. Resection
margin status was assessed for all tumors in these cases.
Data extraction included age, type of surgery (BCS or
mastectomy), tumor size, histological type (according to the
WHO), grade (according to the modified Bloom and
Richardson grading system), ER status, PR status, Her2 status,
the presence, and extent of DCIS. ER and PR status were
defined as positive where more than 10 % of the cancer cells
showed nuclear staining, irrespective of density, according to
the Dutch Guideline for breast cancer treatment.8 Her2 status
was scored according to international guidelines.18
The overall resection margin status was reported as free,
focally irradical, or more than focally irradical, according
to the Dutch Guideline for Breast Cancer Treatment. A free
resection margin is defined as no tumor reaching the ink.
Focally irradical is defined as tumor (either invasive or
DCIS) reaching in the ink in a small area (B4 mm). When
the tumor (either invasive or DCIS) reaches the ink in a
larger area or multiple smaller areas, it is defined as more
than focally irradical.
Statistical Analysis
Univariate and multivariate logistic regression analyses
were performed to test for associations between clinico-
pathologic features and positive resection margins.
Variables that were significant in the univariate analysis
were included in a multivariate model, excluding those
variables that cannot reliably be assessed preoperatively
(presence and extent of DCIS outside the invasive com-
ponent). Analyses were restricted to patients undergoing
BCS. Because there is no international consensus regarding
indications for re-excision, we preformed these analyses
according to two different methods. First, we compared
those patients with a free or focally positive margin to
patients with more than focally positive margins. Second,
because several countries use the definition of ‘‘no ink on
tumor’’ to define resection margin status, we compared
patients with free margins to those with involved margins
(either focally or more than focally).
Two sided p values\ 0.05 were considered significant.
All analyses were performed with SAS Enterprise Guide 7.1.
RESULTS
Patients
Overall, we included 42,048 cases of IBC reported
between January 1, 2009 and September 1, 2015. The
median age of our patient cohort was 62 years (range
18–100). The majority of patients (25,315/42,048; 60.2 %)
underwent BCS. Table 1 provides an overview of clinico-
pathologic data of all patients.
Resection Margin Status
Resection margin status was reported for the majority of
patients undergoing BCS (25,311/25,315 patients). Table 2
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presents the association between several clinicopathological
variables and a more than focally involved resection margin.
Overall, 1665 patients (6.6 %) had more than focally posi-
tive resection margins. Briefly, the following variables were
associated with increased risk of more than focally positive
resection margins in univariate analysis: age \60 years,
multifocality, lobular subtype, large tumor size ([2 cm),
intermediate- and high-grade, positive ER status, positive
Her2 status, angio-invasion, and the presence/extent of a
DCIS component. The following variables were signifi-
cantly associated with more than focally involved margins in
multivariate analysis: age\50 years, multifocality, lobular
subtype, size[2 cm, angio-invasion, and the presence of a
DCIS component. The strongest effect (OR[ 2) was seen
for multifocality, lobular subtype, size [2 cm, and the
presence of DCIS.
We also performed this analysis by comparing free
margin to involved margin (either focally or more than
focally). Table 3 provides an overview of clinicopatho-
logical variables related to involved margins. Overall, 4243
patients (16.8 %) had either focally or more than focally
positive resection margins. In general, univariate results
were similar to those presented in Table 2; exactly the
same variables that were associated with more than focally
involved margins were found when both focally or more
than focally involved margins were analyzed together,
although odd ratios and confidence intervals were slightly
different. Results of multivariate analysis were also com-
parable to the results reported in Table 2, although small
differences were seen. In multivariate analyses, the fol-
lowing variables were significantly associated with focally
or more than focally involved margins: age \50 years,
multifocality, lobular subtype, size[2 cm, grade 2, posi-
tive ER status, positive Her2 status, angio-invasion, and the
presence of a DCIS component. The strongest effect
(OR[ 2) was seen for multifocality, lobular subtype, size
[5 cm, and the presence of DCIS.
DISCUSSION
The majority of patients with IBC are treated with BCS,
followed by irradiation. One of the challenges regarding
BCS is to attain tumor-free resection margins to decrease
the number of second operations and improve local control.
TABLE 1 Baseline characteristics of all patients with IBC
(n = 42,048)
Characteristic Total number of tumors (n = 42.048)
Age at diagnosis Mean 61.2
Median 62 (range 18–100)
Type of surgery, no (%)
Breast-conserving surgery 25.315 (60.2)
Mastectomy 16.733 (39.8)
Tumor type, no (%)
Ductal 33.795 (80.4)
Lobular 5.250 (12.5)
Other 3.003 (7.1)
Multifocality
Yes 3.051 (8.9)
No 31.296 (91.1)
Missing 7.701
Tumor size, no (%)
B2 cm 27.737 (66.0 )
[2–B5 cm 12.656 (30.1)
[5 cm 1.651 (3.9)
Missing 4
Tumor grade, no (%)
1 9.600 (27.0)
2 16.563 (46.6)
3 9.398 (26.4)
Missing 6.487
Estrogen receptor status, no (%)
Positive 34.393 (85.4)
Negative 5.861 (14.6)
Missing 1794
Progesterone receptor status, no (%)
Positive 27.697 (69.0)
Negative 12.462 (31.0)
Missing 1.889
Her2 status, no (%)
Positive 4.224 (11.3)
Negative 33.134 (88.7)
Missing 4.690
Angio-invasion, no (%)
Yes 4.118 (14.0)
No 25.304 (86.0)
Missing 12.626
Presence of DCIS, no (%)
Yes 18.140 (43.1)
No 23.908 (56.9)
DCIS restricted to invasive component, no (%)
Yes 5.882 (54.7)
No 4.878 (45.3)
Missing 7.380
Diameter of DCIS, no (%)
B2 cm 7.982 (67.4)
TABLE 1 continued
Characteristic Total number of tumors (n = 42.048)
[2–B5 cm 2.968 (25.0)
[5 cm 896 (7.6)
Missing 6.294
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TABLE 2 Patient and tumor characteristics of all patients undergoing BCS with available resection margin status (n = 25,311)
Total
(n = 25.311)
Margin free or focally
irradical
Margin more than focally
irradical
OR, univariate analysis
(95 % CI)
OR, multivariate analysis
(95 % CI)
Age at diagnosis, no (%)
\50 4390 4010 (91.34) 380 (8.66) 1.53 (1.35–1.74) 1.22 (1.00–1.49)
50–59 7085 6607 (93.25) 478 (6.75) 1.17 (1.04–1.31) 1.01 (0.85–1.20)
C60 13836 13029 (94.17) 807 (5.83) 1.0 (ref) 1.0 (ref)
Multifocality, no (%)
Yes 773 637 (82.41) 136 (17.59) 3.25 (2.68–3.95) 2.82 (2.14–3.71)
No 19911 18685 (93.84) 1226 (6.16) 1.0 (ref) 1.0 (ref)
Missing 4627
Tumor type, no(%)
Ductal 21143 19889 (94.07) 1254 (5.93) 1.0 (ref) 1.0 (ref)
Lobular 2344 2039 (86.99) 305 (13.01) 2.37 (2.08–2.71) 3.12 (2.48–3.92)
Other 1824 1718 (94.19) 106 (5.81) 0.98 (0.80–1.20) 1.18 (0.88–1.58)
Tumor size, no (%)
B2 cm 19816 18807 (94.91) 1009 (5.09) 1.0 (ref) 1.0 (ref)
[2–B5 cm 5351 4754 (88.84) 597 (11.16) 2.34 (2.11–2.60) 2.01 (1.71–2.37)
[5 cm 144 85 (59.03) 59 (40.97) 12.95 (9.24–18.16) 12.30 (7.12–21.26)
Tumor grade, no (%)
1 6720 6401 (95.25) 319 (4.75) 1.0 (ref) 1.0 (ref)
2 9747 9032 (92.66) 715 (7.34) 1.59 (1.39–1.82) 1.19 (0.99–1.43)
3 5108 4768 (93.34) 340 (6.66) 1.43 (1.22–1.68) 1.03 (0.81–1.31)
Missing 3736
Estrogen receptor status, no (%)
Positive
(C10%)
21182 19739 (93.19) 1443 (6.81) 1.0 (ref) 1.0 (ref)
Negative
(\10%)
3130 2962 (94.63) 168 (5.37) 0.78 (0.66–0.92) 0.94 (0.72–1.21)
Missing 999
Progesterone receptor status, no (%)
Positive
(C10%)
16769 15654 (93.35) 1115 (6.65) 1.0 (ref)
Negative
(\10%)
7518 7024 (93.43) 494 (6.57) 0.99 (0.89–1.10)
Missing 1024
Her2 status, no (%)
Positive 2152 1972 (91.64) 180 (8.36) 1.0 (ref) 1.0 (ref)
Negative 20416 19094 (93.52) 1322 (6.48) 0.76 (0.65–0.89) 0.82 (0.64–1.05)
Missing 2743
Angio-invasion, no (%)
Yes 1784 1581 (88.62) 203 (11.38) 2.02 (1.72–2.37) 1.63 (1.33–2.01)
No 16105 15142 (94.02) 963(5.98) 1.0 (ref) 1.0 (ref)
Missing 7422
Presence of DCIS, no (%)
Yes 11233 10205 (90.85) 1028 (9.15) 2.13 (1.91–2.35) 2.71 (2.29–3.22)
No 14078 13441 (95.48) 637 (4.52) 1.0 (ref) 1.0 (ref)
DCIS outside invasive component, no (%)
Yes 3694 3251 (88.01) 443 (11.99) 2.42 (2.01–2.92)
No 3037 2875 (94.67) 162 (5.33) 1.0 (ref)
Missing 4502
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TABLE 2 continued
Total
(n = 25.311)
Margin free or focally
irradical
Margin more than focally
irradical
OR, univariate analysis
(95 % CI)
OR, multivariate analysis
(95 % CI)
Diameter of DCIS, no (%)
B2 cm 5594 5262 (94.07) 332 (5.93) 1.0 (ref)
[2–B5 cm 1526 1215 (79.62) 311 (20.38) 4.06 (3.43–4.79)
[5 cm 196 125 (63.78) 71 (36.22) 9.00 (6.59–12.30)
Missing 3917
TABLE 3 Patient and tumor characteristics of all patients undergoing BCS with available resection margin status (n = 25,311)
Total
(n = 25.311)
Margin free
(n = 23.646)
Margin focally or more than focally
irradical (n = 1665)
OR, univariate analysis
(95 % CI)
OR, multivariate analysis
(95 % CI)
Age at diagnosis, no (%)
\50 4390 3517 (80.11) 873 (19.89) 1.33 (1.22–1.45) 1.15 (1.00–1.31)
50–59 7085 5889 (83.12) 1196 (16.88) 1.09 (1.01–1.18) 1.05 (0.94–1.18)
C60 13836 11662 (84.29) 2174 (15.71) 1.0 (ref)
Multifocality, no (%)
Yes 773 512 (66.24) 261 (33.76) 2.66 (2.28–3.11) 2.59 (2.09–3.20)
No 19911 16713 (83.94) 3198 (16.06) 1.0 (ref) 1.0 (ref)
Missing 4627
Tumor type, no(%)
Ductal 21143 17777 (84.08) 3366 (15.92) 1.0 (ref) 1.0 (ref)
Lobular 2344 1735 (74.02) 609 (25.98) 1.85 (1.68–2.05) 2.79 (2.38–3.28)
Other 1824 1556 (85.31) 268 (14.69) 0.91 (0.80–1.04) 1.13 (0.93–1.36)
Tumor size, no (%)
B2 cm 19816 16904 (85.30) 2912 (14.70) 1.0 (ref) 1.0 (ref)
[2–B5 cm 5351 4095 (76.53) 1256 (23.47) 1.78 (1.65–1.92) 1.59 (1.42–1.79)
[5 cm 144 69 (47.92) 75 (52.08) 6.31 (4.54–8.77) 5.94 (3.49–10.11)
Missing
Tumor grade, no (%)
1 6720 5808 (86.43) 912 (13.57) 1.0 (ref) 1.0 (ref)
2 9747 8007 (82.15) 1740 (17.85) 1.38 (1.27–1.51) 1.19 (1.06–1.34)
3 5108 4231 (82.83) 877 (17.17) 1.32 (1.19–1.46) 1.14 (0.97–1.33)
Missing 3736
Estrogen receptor status, no (%)
Positive
(C10 %)
21182 17522 (82.72) 3660 (17.28) 1.0 (ref) 1.0 (ref)
Negative
(\10 %)
3130 2685 (85.78) 445 (14.22) 0.79 (0.71–0.88) 0.81 (0.69–0.97)
Missing 999
Progesterone receptor status, no (%)
Positive
(C10 %)
16769 13921 (83.02) 2848 (16.98) 1.0 (ref)
Negative
(\10 %)
7518 6267 (83.36) 1251 (16.64) 0.98 (0.91–1.05)
Missing 1024
Her2 status, no (%)
Positive 2152 1696 (78.81) 456 (21.19) 1.0 (ref) 1.0 (ref)
Negative 20416 17062 (83.57) 3354 (16.43) 0.73 (0.66–0.82) 0.83 (0.70–0.97)
Missing 2743
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In this large population-based cohort study, we reported
several patient and tumor characteristics that are signifi-
cantly associated with an increased rate of tumor-positive
resection margins (irrespective of the definition of irradi-
cality), in particular multifocality, lobular subtype, tumor
size [2 cm, and the presence of a DCIS component.
Because these features can be assessed preoperatively by
imaging and needle biopsy, this provides the opportunity to
improve preoperative counseling regarding optimal sur-
gery. This could reduce the number of re-excisions in those
patients with a substantial risk of involved margins (e.g.,
those with a large lobular carcinoma) by adjustment of
local therapy.
Histologic grade and receptor status were only signifi-
cantly associated with irradicality in multivariate analyses
by comparing patients with free margins to patients with
any involved margins. Receptor status can reliably be
determined on a biopsy specimen.19,20 Histologic grade,
however, may be underestimated, which may not assist in
preoperative counseling.21 There is an increased risk of
irradicality when ER or Her2 receptors are positive. PR
positivity showed the same trend; however, it was not
statistically significant.
Based on a biopsy, the presence of DCIS and angio-
invasion also can be assessed, and, if present, provide
additional information regarding the risk of irradicality.
Obviously, the biopsy only represents a part of the tumor,
so if these factors are absent on the biopsy, it could still be
present in the excision specimen, limiting the value of
these factors preoperatively. Assessment of the extent of
DCIS also is to some extent possible based on a preoper-
ative needle biopsy and imaging. However, this is not
entirely reliable, because a biopsy usually represents the
central invasive component (whereas DCIS can be more
extensive surrounding the invasive component) and imag-
ing modalities are suboptimal for preoperative size
estimation of the DCIS component. Breast imaging by
preoperative MRI is the most sensitive method for esti-
mating the extent of the DCIS component, mainly in the
case of high-grade DCIS, but MRI is not routinely pre-
formed for all patients undergoing BCS.22,23
Our findings are consistent with the literature. However,
the strength of our study is that it represents a nationwide,
consecutive, large series of patients with IBC, resulting in
the largest series published on this subject. One limitation
is that the Dutch distinction between focal and more than
focal tumor-positive resection margins is not applied in
most other European and North American countries. We
adjusted for this by analyzing our data according to both
the Dutch guideline and the SSO/ASTRO guideline, which
defines an adequate margin of IBC as the absence of tumor
reaching the ink. A second limitation is the lack of clinical
follow-up regarding local recurrence and survival, due to
the fact that synoptic reporting only began in 2009. Finally,
a substantial proportion ([10 %) of data were missing for
the following variables: multifocality, grade, Her2 status,
angio-invasion, presence, and extent of DCIS outside the
invasive component.
TABLE 3 continued
Total
(n = 25.311)
Margin free
(n = 23.646)
Margin focally or more than focally
irradical (n = 1665)
OR, univariate analysis
(95 % CI)
OR, multivariate analysis
(95 % CI)
Angio-invasion, no (%)
Yes 1784 1324 (74.22) 460 (25.78) 1.89 (1.68–2.12) 1.56 (1.35–1.80)
No 16105 13600 (84.45) 2505 (15.55) 1.0 (ref) 1.0 (ref)
Missing 7422
Presence of DCIS, no (%)
Yes 11233 8655 (77.05) 2578 (22.95) 2.22 (2.08–2.38) 2.76 (2.48–3.08)
No 14078 12413 (88.17) 1665 (11.83) 1.0 (ref) 1.0 (ref)
Missing
DCIS restricted to invasive component, no (%)
Yes 4120 2884 (70.00) 1236 (30.00) 2.71 (2.41–3.05)
No 3325 2871 (86.35) 454 (13.65) 1.0 (ref)
Missing 3788
Diameter of DCIS, no (%)
B2 cm 5594 4551 (81.36) 1043 (18.64) 1.0 (ref)
[2–B5 cm 1526 889 (58.26) 637 (41.74) 3.12 (2.77–3.53)
[5 cm 196 78 (39.80) 118 (60.20) 6.60 (4.92–8.85)
Missing 3917
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CONCLUSIONS
In this large study, we identified several clinical and
pathological factors that are significantly associated with
involved resections margins after BCS for IBC. Because
the majority of these features are assessed preoperatively,
this provides the opportunity for an optimal preoperative
risk prediction and possibly adjustment of surgical method.
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